The first patient has been treated in a first-in-human clinical trial investigating the safety and efficacy of the CXLens system, a quantitative corneal cross-linking, or qCXL, technology for noninvasive refractive vision correction.“This milestone rep…
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent busine…
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the fourth quarter and full year ended December 31, 2025….
Lawmakers grilled Casey Means, MD, on vaccines, AI, conflicts of interest and more during Wednesday’s Senate hearing to be the next surgeon general.Means, nominated by the Trump administration, was initially set to appear before the U.S. Senate Committ…
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Col…
The FDA cleared an investigational new drug application for NTX-1024 ophthalmic solution in vernal keratoconjunctivitis, paving the way for a phase 2/3 clinical trial, according to a press release from NexEos Bio.A randomized, double-masked, vehicle-co…